Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
तुलना करने के लिए मीट्रिक्स | CHM | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCHMपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.8x | −6.6x | −0.5x | |
PEG अनुपात | −0.07 | −0.26 | 0.00 | |
क़ीमत/बुक | 4.5x | 4.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.7x | 20.3x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 240.6% | 47.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 7.2% | 5.9% | अनलॉक करें |